Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post ASCT in myeloma

Multiple Myeloma (MM)

The bone marrow NK cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy

Blood

Korst CLBM, Tahri S, Duetz C, Bruins WSC, de Jonge AV, de Jong MME, Fokkema C, Smits F, Groen K, Verkleij CPM, Frerichs KA, Papazian N, van Duin M, van Beek G, Hoogenboezem R, Baardemans T, Dal Collo G, Stoetman ECG, Cosovic M, Twickler I, Rentenaar R, Eken M, Homan-Weert PM, Saraci E, D'Agostino M, van der Velden VHJ, Sanders MA, Gay F, Broijl A, Moreau P, Sonneveld P, Zweegman S, Mutis T, Cupedo T, van de Donk NWCJ

doi: 10.1182/blood.2024026455

Multiple Myeloma (MM)

Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)

Blood Cancer J

Derman BA, Major A, Cooperrider J, Jiang K, Ramsland A, Karrison T, Kubicki T, Jakubowiak AJ

doi: 10.1038/s41408-024-01156-x

Multiple Myeloma (MM)

Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial

Lancet Haematol

Cook G, Ashcroft AJ, Senior E, Olivier C, Hockaday A, Richards J, Cavenagh JD, Snowden JA, Drayson MT, de Tute R, Roberts L, Owen RG, Yong K, Garg M, Boyd K, Sati H, Gillson S, Cook M, Cairns DA, Parrish C, United Kingdom Myeloma Research Alliance

doi: 10.1016/S2352-3026(24)00249-7

ASH 2024

Multiple Myeloma (MM)

EMN15/HOVON147: Adding carfilzomib to Rd significantly improves MRD negativity rates in patients with high-risk smoldering multiple myeloma

Multiple Myeloma (MM)

Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival

J Clin Oncol

Pasquini MC, Wallace PK, Logan B, Kaur M, Tario JD, Howard A, Zhang Y, Brunstein C, Efebera Y, Geller N, Giralt S, Hari P, Horowitz MM, Koreth J, Krishnan A, Landau H, Somlo G, Shah N, Stadtmauer E, Vogl DT, Vesole DH, McCarthy PL, Hahn T

doi: 10.1200/JCO.23.00934

Multiple Myeloma (MM)

Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial

Lancet Oncol

Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, Zweegman S, Caillon H, Caillot D, Avet-Loiseau H, Delforge M, Dejoie T, Facon T, Sonntag C, Fontan J, Mohty M, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Macro M, Orsini-Piocelle F, Roussel M, Schiano de Colella JM, van de Donk NW, Wuillème S, Broijl A, Touzeau C, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Offner F, Escoffre-Barbe M, Eveillard JR, Garidi R, Hua W, Wang J, Tuozzo A, de Boer C, Rowe M, Vanquickelberghe V, Carson R, Vermeulen J, Corre J, Sonneveld P, Intergroupe Francophone du Myélome, the Dutch-Belgian Cooperative Trial Group for Hematology Oncology and the CASSIOPEIA Investigators

doi: 10.1016/S1470-2045(24)00282-1

Leukemia

Peripheral blood stem cell versus bone marrow graft for patients ≥60 years undergoing reduced intensity conditioning haploidentical transplantation for acute myeloid leukemia in complete remission: An analysis of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Am J Hematol

Devillier R, Galimard JE, Blaise D, Raiola AM, Bramanti S, Grillo G, Pastano R, de Latour RP, Busca A, López-Corral L, Rodríguez AB, Schmid C, Forcade E, Vydra J, Solano C, Bug G, Neubauer A, Charbonnier A, Brissot E, Nagler A, Ciceri F, Mohty M

doi: 10.1002/ajh.27343

Further Publications

Haploidentical peripheral blood stem cells combined with bone marrow or unrelated cord blood as grafts for haematological malignancies: an open-label, multicentre, randomised, phase 3 trial

Lancet Haematol

Yu S, Huang F, Xu N, Zhang Z, Liu C, Xu X, Fan Z, Zeng X, Liu Q, Qiu G, Xi X, Lin R, Liang X, Jiang Y, Dai M, Jin H, Li X, Wang S, Wu M, Sun J, Xuan L, Liu Q

doi: 10.1016/S2352-3026(24)00372-7

ASH 2024

Multiple Myeloma (MM)

Related content

The bone marrow NK cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy

Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)

Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial

EMN15/HOVON147: Adding carfilzomib to Rd significantly improves MRD negativity rates in patients with high-risk smoldering multiple myeloma

Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival

Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial

Haploidentical peripheral blood stem cells combined with bone marrow or unrelated cord blood as grafts for haematological malignancies: an open-label, multicentre, randomised, phase 3 trial

Isatuximab plus RVd yields deep MRD negativity and PFS benefit in transplant-eligible patients with NDMM